U.S. judge William Bryson ruled that patents covering Allergan‘s (NYSE:AGN) Restasis medicine are invalid on the grounds of obviousness, driving the company’s shares down more than -6% in afternoon trading today.
The decision, made in a Texas federal court, is part of an ongoing case between Allergan and generic drugmakers like Mylan (NSDQ:MYL) and Teva Pharmaceuticals (NYSE:TEVA).
Get the full story at our sister site, Drug Delivery Business News.
The post Texas judge rules Allergan’s Restasis patents invalid appeared first on MassDevice.
from MassDevice http://ift.tt/2gfN9sc
Cap comentari:
Publica un comentari a l'entrada